Treatment of Tourette's syndrome with transdermal clonidine: a pilot study
Abstract
Nine patients with mild Tourette's syndrome completed a cross-over, placebo-controlled study of clonidine administered transdermally. Although the subjects showed no improvement on objective measures of symptom severity, most subjects felt they had improved. Seven subjects chose to continue taking clonidine. Larger, blinded studies of transdermal clonidine are indicated.
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.- Personal login
- Institutional Login
- Sign in via OpenAthens
- Register for access
-
Please login/register if you wish to pair your device and check access availability.
Not a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).
